Prostate cancer patients who are treated with a combination of hormone therapy and radiation have a substantially improved chance of survival compared to patients who do not receive radiation, according to interim results of the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting [...]
Many men with metastatic prostate cancer will suffer compression fractures in their spine. Since the spine is one of the most common sites for metastatic spread of the disease, the vertebrae often become brittle and at a very high risk for fractures. Hormone therapy and radiation therapy can also have a weakening effect on bone [...]
An article published Online First and in an upcoming edition of The Lancet Oncology reports that an oral bisphosphonate, sodium clodronate, improves overall survival in men with advanced prostate cancer. However, it does not reduce the risk of death in men with localized disease. These are the final results of the MRC PR05 and MRC [...]
Just revealed in briefing documents which were released in advance of a scheduled Thursday meeting of the FDA’s Advisory Committee for Reproductive Health Drugs, which will be considering whether to recommend denosumab for approval, are significant concerns that denosumab, the investigational biologic drug for osteoporosis, may increase risk of serious infections through its activity against [...]
— A New Trial Marks Expanded Phase 3 Development of MDV3100 into Earlier-Stage Disease — Medivation, Inc. and Astellas Pharma Inc. today announced the launch of a second Phase 3 clinical trial of their investigational drug MDV3100. This trial marks the expansion of the Phase 3 development of their novel, triple-acting oral androgen receptor antagonist [...]